Skip to Content

Relacorilant (LIFYORLI) and Albumin-Bound Paclitaxel (Nab-Paclitaxel) for Platinum-Resistant Ovarian Cancer

Download PQI pdf

Last Updated: September 9, 2026

By: Courtney Arn, APRN-CNP

About this PQI

The purpose of this document is to review the novel mechanism of action, appropriate patient selection, management of potential adverse effects, and other clinical considerations related to relacorilant administration in conjunction with nab-paclitaxel.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI